

Biogen Idec, Elan apply for MS drug label update

Mass High Tech: The Journal of New England Technology

Biogen Idec Inc. and Elan Corp. plc, the co-owners of multiple sclerosis drug Tysabri, have sent a recommendation to the U.S. Food and Drug Administration and the European Medicines Agency to [update the labeling](#) [1] of the drug in order to clarify the risk of a rare but potentially fatal brain infection.

The two companies have proposed that labeling of Tysabri include anti-JC Virus antibody status as a factor related to the risk of progressive multifocal leukoencephalopathy (PML), the name of the brain infection.

[SOURCE](#) [2]

Source URL (retrieved on 01/27/2015 - 6:57pm):

<http://www.mdtmag.com/news/2010/12/biogen-idec-elan-apply-ms-drug-label-update>

Links:

[1] http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1509977

[2] <http://www.masshightech.com/stories/2010/12/20/daily52-Biogen-Idec-Elan-apply-for-MS-drug-label-update.html>